Last reviewed · How we verify
NCT06858345: CARDIAC-OAT
Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy
trial in Preeclampsia in 50 participants. Currently enrolling.
15 January 2026
Quick facts
| Lead sponsor | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2025 |
| Primary completion | 15 January 2026 |
| Estimated completion | 15 January 2026 |
| Sites | 1 location across Spain |
Conditions studied
- Preeclampsia — all drugs for Preeclampsia →
Sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — full company profile →
Who can join
18 and older, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06858345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preeclampsia
Currently open trials in the same condition.
- NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
- NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
- NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
- NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
- NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
Other Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia trials
Trials by the same sponsor.
- NCT07064811 — Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivati · NA · not yet recruiting
- NCT06646562 — Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. · Phase 4 · recruiting
- NCT06874907 — First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring. · recruiting
- NCT06713486 — Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndro · NA · not yet recruiting
- NCT06449430 — Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06858345 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06858345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing